Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Quidel Corporation    QDEL   US74838J1016

QUIDEL CORPORATION

 (QDEL)

1
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 

Quidel : Quidel to Hold 2007 First Quarter Financial Results Conference Call on April 26

04/19/2007| 07:00am US/Eastern
Recommend:
0

Quidel Corporation (Nasdaq:QDEL), a leading provider of rapid point-of-care diagnostic tests, will release 2007 first quarter financial results after market close on Thursday, April 26, 2007.

Following the release of the results, Caren L. Mason, president and chief executive officer, and John M. Radak, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. ET (2:00 p.m. PT) to discuss those results and to answer questions.

To participate in the live call by telephone from the U.S., dial (888) 803-7396, or from outside the U.S. dial (706) 634-1052. A live webcast of the call can be accessed at www.quidel.com. The web site replay will be available for 14 days and the telephone replay will be available for 48 hours by dialing (800) 642-1687 from the U.S., or (706) 645-9291 for international callers, and entering reservation number 5521515.

About Quidel

Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue®, Quidel's portfolio of products currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, respiratory syncytial virus, Fecal Occult Blood, Strep A, pregnancy, bacterial vaginosis, infectious mononucleosis, H. pylori and Chlamydia. Quidel's products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel's Specialty Products Group (SPG) develops research products in the fields of oncology and bone health with potential future point-of-care applications. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment has an impact on clinical outcomes and provides an economic benefit. For more information, visit www.quidel.com, www.flutest.com, or www.colorectal-test.com.


© Business Wire 2007
Recommend :
0
Partner Area
React to this article
 
Latest news on QUIDEL CORPORATION
05/08 QUIDEL CORPORATION: Quidel to Present at Bank of America Merrill Lynch 2013 Hea..
05/06 QUIDEL CORPORATION: Quidel Completes Acquisition of BioHelix Corporation
04/23 QUIDEL CORPORATION: Quidel Reports First Quarter 2013 Financial Results
04/10 QUIDEL CORPORATION: Quidel to Hold First Quarter 2013 Financial Results Confere..
03/25 QUIDEL CORPORATION: Quidel Receives CE Mark for Its Molecular Diagnostic Test f..
03/18 QUIDEL CORPORATION: Quidel and Life Technologies Receive FDA Clearance for Clos..
03/12 QUIDEL CORPORATION: Quidel Receives FDA Clearance for Its Molecular Diagnostic ..
02/25 QUIDEL CORPORATION: Quidel to Host 2013 Analyst and Investor Day in Boston
02/25 QUIDEL CORPORATION: Quidel to Present at Cowen 33rd Annual Health Care Conferen..
02/12 QUIDEL CORPORATION: Quidel Reports Fourth Quarter and Full Year 2012 Financial ..
Advertisement
Chart
Duration : Period :
Quidel Corporation Technical Analysis Chart | QDEL | US74838J1016 | 4-Traders
Income Statement Evolution
Quidel Corporation : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.